

## This week in therapeutics

| Indication                | Target/marker/<br>pathway                              | Summary   | Licensing<br>status                                     | Publication and contact<br>information  |
|---------------------------|--|---|---|---|
| <b>Autoimmune disease</b> |  |   |   |   |
| Rheumatoid arthritis (RA) | Sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) | <p>Mouse studies suggest an S1P1 antagonist might help treat RA and other autoimmune indications. In two mouse models of collagen-induced arthritis, the antagonist suppressed disease or decreased disease severity compared with vehicle. Next steps could include evaluating the S1P1 antagonist in additional autoimmune disease models.</p> <p><b>SciBX 5(1); doi:10.1038/scibx.2012.6</b><br/>Published online Jan. 5, 2012</p> | Patent applications filed; licensing status unavailable | <p>Fujii, Y. <i>et al. J. Immunol.</i>; published online Nov. 30, 2011; doi:10.4049/jimmunol.1101537</p> <p><b>Contact:</b> Yasuyuki Fujii, Taisho Pharmaceutical Co. Ltd., Saitama, Japan<br/>e-mail: <a href="mailto:y.fujii@po.rd.taisho.co.jp">y.fujii@po.rd.taisho.co.jp</a></p> |